Le Lézard
Classified in: Health, Science and technology
Subject: MRR

Hospital Logistics Robots Global Market Report 2023: Rising Need for Remote Care Fuels Sector Growth

DUBLIN, March 23, 2023 /PRNewswire/ -- The "Hospital Logistics Robots Market by Type and Application - Global Opportunity Analysis and Industry Forecast 2022-2030" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

Hospital Logistics Robots Market size was valued at USD 971.25 million in 2021, and is predicted to reach USD 5637.85 million by 2030, with a CAGR of 21.2% during the forecast period, 2022 to 2030.

Demand for hospital logistics robots has increased across the globe, owing to rise in need for remote care, such as telemedicine and telehealth. These robots can be used to remotely transport medical equipment and supplies, as well as assist with tasks such as monitoring patients remotely. This can help minimize human-to-human contact and keep hospital staff and patients safe.

However, high costs associated with the integration of logistics robots hamper the market growth. On the contrary, rise in advancements in Artificial Intelligence (AI) and Machine Learning (ML) as these technologies can be used to improve capabilities and performance of these robots is expected to create ample opportunities for key players operating in the hospital logistics market in the coming decade.

AI and ML are used in hospital logistics robots for route optimization, predictive maintenance, task prioritization, machine vision & object detection, natural language processing (NLP), and reinforcement learning.

Segment Overview

The global hospital logistics robots market is segmented on the basis of type, application, and region.

Regional Analysis

North America market is projected to hold a dominant share by 2030.

The region dominates the hospital logistics robots market and is potently expected to remain dominant throughout the forecast period. This is attributed to implementation of Industry 4.0 technologies such as IoT and cloud-based systems that enable real-time tracking, monitoring, and control of hospital logistics robots. This improves collaboration and communication between different systems and devices, which is expected to drive the market growth in the region.

Furthermore, various prominent players including ABB Ltd., Teradyne Inc., and Aethon are adopting various market strategies such as expansions and product launches to expand their market presence across the region.

Key Market Players

Emerging and efficient key players in the hospital logistics robots industry research include companies such as:

Recent Developments

December 2022

ABB expanded its operation in Shanghai, China by opening a new 67,000-square-meter robotics factory to maximize productivity. These production cells are digitally connected and networked. Robotic systems perform tasks include screwdriving, assembling, and material handling. Autonomous mobile robots (AMRs) zip around the facility ensuring all of the production cells are kept up to date.

May 2022

Locus Robotics expanded and introduced new AMRs to its intelligent warehouse execution platform for end-to-end optimization. These AMRs meet a broad range of warehouse use cases from e-commerce, case-picking, and pallet-picking to scenarios requiring larger, heavier payloads to support the full range of product movement in distribution warehouses.

May 2022

A new robotic software, RoMi-H was introduced by CGH's Centre for Healthcare Assistive and Robotics Technologies, the Integrated Health Information Systems, and engineering firms Hope Technik and Open Source Robotics. It aims to provide a common language for robots to interact with hospital building infrastructure including lifts.


Key Topics Covered:

1. Introduction

2. Hospital Logistics Robots Market - Executive Summary

3. Market Overview

4. Market Share Analysis

5. Global Hospital Logistics Robots Market, by Type

6. Global Hospital Logistics Robots Market, by Application

7. Global Hospital Logistics Robots Market, by Region

8. Company Profiles

A selection of companies mentioned in this report includes

For more information about this report visit https://www.researchandmarkets.com/r/qk4z7r

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

These press releases may also interest you

at 13:35
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ?50%...

at 12:17
Sanctuary Cannabis, a trusted provider of high-quality medical cannabis products, is excited to announce the grand opening of its 19th medical cannabis dispensary in Boynton Beach, Florida....

at 12:00
?  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses?? ? ...

at 09:10
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample. Notably, Exai's platform maintained...

at 09:05
Cyteir Therapeutics, Inc. ("Cyteir") , a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate...

at 09:05
Merck , known as MSD outside of the United States and Canada, today announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment...

News published on and distributed by: